Sigyn Therapeutics Inc
(SIGY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 54 | 33 | 12 | 65 | 24 |
| Inventories | 50 | 50 | 50 | 50 | 50 |
| Other current assets | 43 | 52 | 56 | 54 | 55 |
| TOTAL | $146 | $134 | $118 | $169 | $129 |
| Non-Current Assets | |||||
| PPE Net | 12 | 14 | 15 | 17 | 19 |
| Other Non-Current Assets | 161 | 175 | 188 | 202 | 214 |
| TOTAL | $174 | $189 | $204 | $218 | $233 |
| Total Assets | $320 | $323 | $322 | $387 | $362 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,780 | 2,477 | 2,210 | 2,948 | 2,630 |
| Accounts payable and accrued liabilities | 488 | 530 | 1,253 | 362 | 340 |
| Accrued Expenses | 1,493 | 1,078 | N/A | 405 | 186 |
| Other current liabilities | 72 | 88 | 83 | 47 | 32 |
| TOTAL | $3,900 | $4,235 | $3,608 | $3,821 | $3,246 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 93 | 110 | 126 | 142 | 158 |
| TOTAL | $93 | $110 | $126 | $142 | $158 |
| Total Liabilities | $3,992 | $4,345 | $3,734 | $3,963 | $3,404 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,264 | 1,225 | 1,224 | 1,288 | 1,106 |
| Common Shares | 0 | 0 | 0 | 4 | 4 |
| Retained earnings | -12,962 | -12,100 | -11,342 | -10,166 | -9,260 |
| TOTAL | $-3,672 | $-4,021 | $-3,413 | $-3,576 | $-3,042 |
| Total Liabilities And Equity | $320 | $323 | $322 | $387 | $362 |